Allosteric Activation of Striatal-Enriched Protein Tyrosine Phosphatase (STEP, PTPN5) by a Fragment-like Molecule

被引:27
作者
Tautermann, Christofer S. [1 ]
Binder, Florian [1 ]
Buettner, Frank H. [2 ]
Eickmeier, Christian [1 ]
Fiegen, Dennis [1 ]
Gross, Ulrike [1 ]
Grundl, Marc A. [1 ]
Heilker, Ralf [2 ]
Hobson, Scott [3 ]
Hoerer, Stefan [1 ]
Luippold, Andreas [2 ]
Mack, Volker [3 ]
Montel, Florian [1 ]
Peters, Stefan [1 ]
Bhattacharya, Supriyo [4 ]
Vaidehi, Nagarajan [4 ]
Schnapp, Gisela [1 ]
Thamm, Sven [2 ]
Zeeb, Markus [1 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Med Chem, Birkendorfer Str 65, D-88397 Biberach, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Drug Discovery Sci, Birkendorfer Str 65, D-88397 Biberach, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, CNS Dis Res, Birkendorfer Str 65, D-88397 Biberach, Germany
[4] Beckman Res Inst City Hope, Dept Mol Immunol, 1500 E Duarte Rd, Duarte, CA 91010 USA
关键词
ALZHEIMERS-DISEASE; INHIBITION; IDENTIFICATION; EXPRESSION; REDUCTION; SUBSTRATE; DEFICITS; PTP1B;
D O I
10.1021/acs.jmedchem.8b00857
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein tyrosine phosphatase non-receptor type 5 (PTPN5, STEP) is a brain specific phosphatase that regulates synaptic function and plasticity by modulation of N-methyl-D-aspartate receptor (NMDAR) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) trafficking. Dysregulation of STEP has been linked to neurodegenerative and neuropsychiatric diseases, highlighting this enzyme as an attractive therapeutic target for drug discovery. Selective targeting of STEP with small molecules has been hampered by high conservation of the active site among protein tyrosine phosphatases. We report the discovery of the first small molecule allosteric activator for STEP that binds to the phosphatase domain. Allosteric binding is confirmed by both X-ray and N-15 NMR experiments, and specificity has been demonstrated by an enzymatic test cascade. Molecular dynamics simulations indicate stimulation of enzymatic activity by a long-range allosteric mechanism. To allow the scientific community to make use of this tool, we offer to provide the compound in the course of an open innovation initiative.
引用
收藏
页码:306 / 316
页数:11
相关论文
共 43 条
  • [1] THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY
    BAILEY, S
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 : 760 - 763
  • [2] Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome
    Barr, Alastair J.
    Ugochukwu, Emilie
    Lee, Wen Hwa
    King, Oliver N. F.
    Filippakopoulos, Panagis
    Alfano, Ivan
    Savitsky, Pavel
    Burgess-Brown, Nicola A.
    Mueller, Susanne
    Knapp, Stefan
    [J]. CELL, 2009, 136 (02) : 352 - 363
  • [3] Differences in Allosteric Communication Pipelines in the Inactive and Active States of a GPCR
    Bhattacharya, Supriyo
    Vaidehi, Nagarajan
    [J]. BIOPHYSICAL JOURNAL, 2014, 107 (02) : 422 - 434
  • [4] Insights into the Reaction of Protein-tyrosine Phosphatase 1B CRYSTAL STRUCTURES FOR TRANSITION STATE ANALOGS OF BOTH CATALYTIC STEPS
    Brandao, Tiago A. S.
    Hengge, Alvan C.
    Johnson, Sean J.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (21) : 15874 - 15883
  • [5] The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications
    Carty, N. C.
    Xu, J.
    Kurup, P.
    Brouillette, J.
    Goebel-Goody, S. M.
    Austin, D. R.
    Yuan, P.
    Chen, G.
    Correa, P. R.
    Haroutunian, V.
    Pittenger, C.
    Lombroso, P. J.
    [J]. TRANSLATIONAL PSYCHIATRY, 2012, 2 : e137 - e137
  • [6] Case D.A., 2014, Amber 14, V14
  • [7] Chemical Computing Group, 2017, MOL OP ENV MOE VERS
  • [8] MolProbity: all-atom structure validation for macromolecular crystallography
    Chen, Vincent B.
    Arendall, W. Bryan, III
    Headd, Jeffrey J.
    Keedy, Daniel A.
    Immormino, Robert M.
    Kapral, Gary J.
    Murray, Laura W.
    Richardson, Jane S.
    Richardson, David C.
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 : 12 - 21
  • [9] Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
    Chen, Ying-Nan P.
    LaMarche, Matthew J.
    Chan, Ho Man
    Fekkes, Peter
    Garcia-Fortanet, Jorge
    Acker, Michael G.
    Antonakos, Brandon
    Chen, Christine Hiu-Tung
    Chen, Zhouliang
    Cooke, Vesselina G.
    Dobson, Jason R.
    Deng, Zhan
    Fei, Feng
    Firestone, Brant
    Fodor, Michelle
    Fridrich, Cary
    Gao, Hui
    Grunenfelder, Denise
    Hao, Huai-Xiang
    Jacob, Jaison
    Ho, Samuel
    Hsiao, Kathy
    Kang, Zhao B.
    Karki, Rajesh
    Kato, Mitsunori
    Larrow, Jay
    La Bonte, Laura R.
    Lenoir, Francois
    Liu, Gang
    Liu, Shumei
    Majumdar, Dyuti
    Meyer, Matthew J.
    Palermo, Mark
    Perez, Lawrence
    Pu, Minying
    Price, Edmund
    Quinn, Christopher
    Shakya, Subarna
    Shultz, Michael D.
    Slisz, Joanna
    Venkatesan, Kavitha
    Wang, Ping
    Warmuth, Markus
    Williams, Sarah
    Yang, Guizhi
    Yuan, Jing
    Zhang, Ji-Hu
    Zhu, Ping
    Ramsey, Timothy
    Keen, Nicholas J.
    [J]. NATURE, 2016, 535 (7610) : 148 - +
  • [10] Conformational Rigidity and Protein Dynamics at Distinct Timescales Regulate PTP1B Activity and Allostery
    Choy, Meng S.
    Li, Yang
    Machado, Luciana E. S. F.
    Kunze, Micha B. A.
    Connors, Christopher R.
    Wei, Xingyu
    Lindorff-Larsen, Kresten
    Page, Rebecca
    Peti, Wolfgang
    [J]. MOLECULAR CELL, 2017, 65 (04) : 644 - +